Trimeris and Roche Pharmaceuticals -- makers of the fusion inhibitor Fuzeon -- presented early data on two new fusion inhibitors, called TR-290999 and TR-291144. The most notable feature of these two drugs is that they are being developed for possible once a week -- with some quiet suggestion of even less frequent dosage.
El era joven y torpe y estaba enamoradoParaCrawl Corpus ParaCrawl Corpus